BioPharma Dive June 28, 2021
Sponsored content By Koneksa Health

During the height of the COVID-19 pandemic, numerous clinical trials were paused or transitioned, if possible, to virtual or hybrid clinical trials. These types of trials leveraged a variety of modalities, including telemedicine, remote visits, and various sensors or wearable technology.

Not all disease indications or types of trials are suitable for virtual or hybrid clinical trials, although often components of hybrid trials might be suitable for most studies. Wearables, for example, such as smartwatches and exercise monitors, can provide a wealth of real-time physiological data that can be applied to a broad range of investigations, ranging from preclinical studies to determine patient suitability, through Phase I, II and III clinical trials, and in post-approval studies for enhanced monitoring for...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology, Wearables
Too much data? Wearables for senior care have value but providers must know how to parse their output, experts say
'From Interpretation to Action': Using CGM to Manage T2D
Roche develops continuous glucose monitor with predictive algorithms
Novosound locks down patent for wearable ultrasound imaging platform
Wearable Technology Transforms Clinical Trials with Continuous Remote Monitoring

Share This Article